Do you want to buy antibiotics online without prescription? https://buyantibiotics-24h.com/ - This is pharmacy online for you!
Efficacia del citalopram nel trattamento della bulimia nervosa : uno studio randomizzato e controllato
Biomedical Research 2005; 16 (2): 85--87
Treatment of bulimia nervosa with citalopram: A randomized controlled
W. Milano, C. Petrella, *A. Capasso
Unità Operativa di Salute Mentale Distretto 44 ASL NA1, Via Monte di Dio, 25. Napoli, Italy
*Department of Pharmaceutical Sciences, University of Salerno, via Ponte Don Melillo, Fisciano (Salerno), Italy Key words
: Bulimia nervosa, serotonin, SSRI
Bulimia nervosa (BN) is one of the most frequent eating disorders in industrialized societies. Re-
duced serotonin activity has been suggested to trigger some of the cognitive and mood distur-
bances associated with BN. Therefore, pharmacological treatment of BN is mainly based on the use
of selective serotonin reuptake inhibitors, that have proved effective. The biological basis of this
disorder fully are not established yet.
The aim of this randomized controlled trial was to verify the efficacy of citalopram, a selective sero-
tonin reuptake inhibitor, in a group of BN diagnosed patients.
Twenty female outpatients, with an age range of 19-28 years having BN-binge purging, as defined by
the DSM IV, were assigned randomly into two treatment groups; the first group received 20-40
mg/day citalopram for 12 weeks and the second group had placebo. The study was conducted for 12
weeks with weekly clinical assessments.
At the end of the observation period, the group treated with citalopram showed a statistically signifi-
cant reduction in the number of binge-eating crisis and purging with respect to the group who re-
ceived the placebo only. In no case, treatment was interrupted for any emergency reasons.
This study indicates that citalopram is well tolerated and equally effective in reducing binge-eating
crisis and purging in patients with BN
Stuncard in the ‘50s) regarding the quantities of food taken and
patient’s lack of control on eating impulse (criterion A).
The term bulimia nervosa (BN) refers to an eating behaviour
characterised by episodes of convulsive greedy uncontrolled
Moreover, the DSM IV identifies two subtypes: with
ingestion of high caloric and easy-taking food in great quantities.
haviours (self-induced vomiting, misuse of laxatives or diuretics,
Compensatory behaviours to control the weight often follow
etc.) and without
purging behaviours, when the patient uses
these episodic crises, such as self-induced vomiting or laxatives
fasting or excessive physical exercises and no medicines or
vomiting (criterion B). The first type is obviously the most seri-
Even if the bulimic patient has nearly normal weight or of slightly
excess, its stability is very fragile because the idea of putting on
The clinical complications of BN are mainly linked to the chaos
in eating, but especially to the compensatory episodes which
can provoke side effects, such as the erosion of the dental
In 1980 the DSM III included the BN in the official diagnostic
eamel or the inflammation of the esophageal mucosa, up to hy-
nomenclature. In 1994 the DSM IV defined the peculiarities of
dro-electrolytic imbalances which can cause arrhythmia, cardiac
the bulimic crisis (binge-eating – the term first used by Albert
The bulimic patients show nearly always mood disorders (de-
Results and Discussion
pression), abnormal behaviours such as alcohol or drugs misus-
ing, self-damaging behaviour, panic crisis, obsessive-compul-
Following eight weeks of treatment, the group given citalopram
showed 65% reduction in the bulimic seizures and 56% de-
crease in the purging behaviours. The average caloric intake
Recent theories refer to BN as a serotoninergic system disfunc-
was decreased into 7%, and there was a strong reduction in the
tion. The serotonin (5HT) concentration declines in the cerebro-
glicide rate. The patients lost about 5% of their body weight
spinal fluid of those bulimic patients who show more binge-
eating behaviours. The serotoninergic theory also explains other
psycho-pathologic aspects which are often linked to the eating
The second group with placebo showed 12% reduction in the
bulimic seizures and 7% decrease in the purging behaviours.
The average caloric intake and body weight showed no signifi-
This hypothesis possibly provokes the use of anti-depression
psychotropic drugs as symptomatologic therapy in BN. In recent
years, selective inhibitor of serotonin’s reuptake (SSRI) is fa-
During the course of treatment, the following side effects were
The group given citalopram showed 38% sedation, 24%
Our study aims at testing the efficacy of citalopram the most se-
mouth dryness, 6% nausea and 3% headache.
lective SSRI, in symptomatologic treatment of BN.
The group which had placebo showed 9% headache, 12% light asthenia and 5% sedation (Table 1).
Materials and Methods
None of the patient went out of the trial because of serious side effects.
The study included 20 female patients, aged between 19 and 28
who suffered from BN with purging behaviours (BN - binge purg-
Our results therefore suggest that the use of citalopram in the
ing) according to the DSM IV and the BITE scale’s diagnostic
symptomatological treatment of BN has a prononced clinic
criteria. The patients, with their consent, were randomly divided
value. The bulimic patients who were given citalopram have,
into two groups of 10 women in each. The patients in the first
indeed, showed a statistically significant decrease both in binge-
group were given citalopram of 20 mg/day for the first week and
eating crises and purging episodes, together with a reduced cra-
40 mg/day during the following seven weeks. The patients in the
ving for carbohydrates and, even if indirectly, a modest average
second group were given placebo. The study went on for eight
caloric intake, which has caused a slight weight loss at the end
weeks. All patients were subjected to clinical check-up (twice-a-
of the trial. Moreover, no patient treated with citalopram or pla-
week for the period of 8 weeks) in order to monitor the clinical
cebo suffered from any drug-induced side effects. These encou-
development and the possible side effects if any. The patients
raging results therefore us to suggest that the use of citalopram
had maintained an accurate diary of their food choices, bulimic
in the symptomatological treatment of BN is as an effective al-
seizures, weight and the possible compensatory behaviours.
Table 1: The effects of citalopram vs placebo in BN
Citalopram Treated Patients
Placebo Treated Patients
1. Muscettola G, Casiello M. Psicofarmacologia dei disordini del
comportamento alimentare. In: Bellan tuono, Balestrino Glips
icofarmaci: farmacologia e terapia. Pensiero Scientifico
2. American Psychiatric Association. Diagnostic and Manual
3. Walsh T, Devlin M. Eating disorders: progress and prob
4. Cuzzolaro M, Magnani M. Obesità e disturbi del com porta
mento alimentare. In: Borsello O. Obesità Ed Kurtis 1998;
5. Bellodi L, Brambilla F. Eating disorders and obsessive
compulsive disorders: an pathogenetic link? Centro Scientif
6. Brewerton TD. Toward a unifed theory of serotonin dysregu
lation in eating and related disorders.Psycho endocrinol
7. Ramacciotti C. Terapia farmacologica della Bulimia Ner
8. Liebbowiz SF et al. Brain serotonin and eating behav-
9. Jiemeron DC et al.: Decreased serotonin function in B.N.
10. Muller E, Brambilla F. Disordini del comportamento alimen
11. Devane CL Comparative safety and tolerability of SSRI.
Human Psychopharmacology 1995; 10: 185-193
12. Henderson M, Freeman CP. A Self-rating scale for bu
limia. The BITE. Brit Jour Psychtr 1987; 150: 18-24.
13. American Psychiatric Association: Practice guideline for the
treatment of patients with eating disorder. Am J Psychiatry
14. Kay WH: Serotonin regulation in bulimia. The psycho-
biology of bulimia. In: Hudsen J Editor 1987; 2: 54-66.
6-B Manzar, Sir Syed Nagar, Aligarh 202 002, India
Dr. Anna Capasso Department of Pharmaceutical Sciences University of Salerno via Ponte Don Melillo
(84084) Fisciano (Salerno)
Treatment of Binge Eating Disorder with Sertraline: A Ran-
domized Controlled Trial.
Biomedical Research 2005; 16 (2):
Authors: W. Milano, Petrella C., Capasso A
Charge for 3 printed pages (short paper)
Treatment of bulimia nervosa with citalopram: A randomized controlled trial
Biomedical Research 2005; 16 (2):
Authors: W. Milano, C. Petrella, A. Capasso
Charge for 3 printed pages (short paper)
US$ Five Hundred Only
Payment be made by Bank Draft in Indian Rupees in favour of
Biomedical Research, Account No. 01050081005
State Bank of India, Main Branch, Aligarh 202 002, India
Sir Syed Nagar Aligarh 202 002, India
SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING1.2. Relevant identified uses of the substance or mixture and uses advised againstHARDENER FOR TWO COMPONENT Primer. and Crack and hole filler1.3. Details of the supplier of the safety data sheetCOO-VARLockwood StreetHullHU2 0HN+44 (0) 1482 328053(T)+44 (0) 1482 219266(F)firstname.lastname@example.orgTechnical Department
Agenda Advancing economics in business Shades of grey: arguments for and against parallel trade in pharmaceuticals Last month the European Court of Justice announced its judgment on Syfait v GlaxoSmithKline, the latest case concerning parallel trading (aka grey imports). One of the most pressing competition issues facing the pharmaceutical industry, this topic was discussed during the seco